Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Bayer Receives FDA Fast-Track Designation for Next-Generation Anticoagulant.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Subject Terms:
- Abstract:
The article reports on the Fast-Track designation received by Bayer from the U.S. Food and Drug Administration (FDA) for its investigational anticoagulant asundexian (BAY243334). Topics discussed include information on asundexian, how to receive Fast Track designation, and clinical trials that are evaluating proper dosing and safety of asundexian.
No Comments.